


In response to the Restriction Requirement mailed August 11, 2004, Applicants hereby elect Group I with traverse in order to comply with 37 CFR 1.143.

Without comment to the possible existence of multiple independent and/or distinct inventions, Applicants note that MPEP § 803 states that even if two or more claim groupings are independent or distinct as claimed, there must also be a serious burden on the examiner to require restriction. If the search and examination of the entire application can be made without serious burden, the examiner must examine the entire application. See MPEP §803. Applicant submits that searching between various chemotherapeutic agents and radiosensitizers is not a serious burden since the targeting moiety, chelator, etc. will remain the same.

Regarding the election of a single species for search purposes, Applicants elect a species where the chemotherapeutic agent is gemcitabine and the radiopharmaceutical is:



Said structure can be found in Applicants' specification at p.177.


DOCKET NO.: BMS-2288/DM-6958A
Application No.: 10/622,246
Office Action Dated: August 11, 2004

PATENT

If the Examiner has any questions, she is invited to call the undersigned representative
at (215) 568-3100.

Date: _____

Oct. 12, 2004



Brian J. Hubbard
Registration No. 45,873

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439